With over 500 million clinical cases each year, malaria still remains a major threat in the world, as more than two million people succumb from the disease each year. The high prevalence of the disease is attributed to the difficulties in vector control, as well as the increasing resistance of Plasmodium falciparum, the main causative agent of the disease, towards the commonly used antimalarials such as chloroquine. Therefore, new antimalarial drugs acting on alternative, yet unexplored biochemical pathways are urgently needed.
Recently, the discovery of the mevalonate-independent pathway for isoprenoid biosynthesis opened the way for new therapeutics to cure malaria, as this alternative pathway is absent in humans. Two groups simultaneously discovered that fosmidomycin effectively inhibits 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR). 1, 2 This essential enzyme converts 1-deoxy-D-xylulose 5-phosphate (DOXP) to 2C-methyl-D-erithrytol phosphate (MEP), the second step in the non-mevalonate pathway. In recent clinical trials fosmidomycin combinations with clindamycin 3 or artesunate 4 were found very efficient in curing P. falciparum uncomplicated malaria (Figure 1) . FR900098, the acetyl congener of fosmidomycin, was found to be twice as active as fosmidomycin, both in vitro and in a P. vinckei mouse model. 2 For structure-activity relationship analyses of fosmidomycin derivatives, various alterations have been made, mainly addressing the retrohydroxamate and phosphonate moieties. [5] [6] [7] [8] [9] Comparatively few modifications of the carbon spacer have been explored. Hence, we recently focused on such type of modifications. (Figure 1) Incorporation of aryl functionalities in -position of the phosphonate of fosmidomycin (e.g., 1) or FR900098 resulted in a markedly enhanced in vitro antiplasmodial activity, which proved to be associated to the electron withdrawing properties of the aryl substituents. 10, 11 Based on a reported prodrug approach, 6 Kurz et al. systematically investigated the effect of introduction of different substituents in α-position of the bis(pivaloyloxymethyl) esters of fosmidomycin or FR900098. 12, 13, 14 Introduction of an -methyl or -phenyl substituent afforded analogues, which exhibited antiplasmodial activities that came close to that of the FR900098 prodrug, while a 3,4-difluorophenylsubstituted analogue was slightly more potent. Consistent with our findings, -aryl-substituted fosmidomycin analogues were generally superior to their FR900098 homologues. The introduction of an ethyl, propyl, isopropyl, dimethyl and hydroxymethyl group was associated with a considerable drop in antimalarial activity. 12 Also -arylmethyl 13 or phenylethyl 14 analogues failed to surpass the activities of the -aryl prodrugs. Furthermore, rigidification of the carbon spacer by the introduction of a cyclopropane 15 (as in 2) or cyclopentane 11 ring, indicated a preferred trans geometry for the substituents on these rings for binding DXR.
The scope of the present work is to combine both features, i.e. rigidification of the carbon spacer (through incorporation of an ,-unsaturated bond) and introduction of an -aryl substituent. As the ,-double bond could occur both in the E-or in the Zconfiguration, these analogues might provide insight in the preferred binding conformation of saturated α-substituted fosmidomycin analogues. The retrosynthetic approaches towards the synthesis of the Z-and E-configured analogues of FR900098 are briefly depicted in Scheme 1. The synthesis of the Zanalogues 3a-e is based on a palladium(0)-catalysed Stille-coupling on organotin derivative 5, 16 while the synthesis of the E-configured analogues 4a,f-g features a Suzuki-type cross-coupling on vinylic bromide 6 as a key-step. The synthesis of compounds 8a-e in 5 steps from THPprotected propargyl alcohol 7 via Stille coupling of 5 (Scheme 2) was recently reported as part of a divergent synthetic route towards α-substituted fosmidomycin analogues. 16 Due to the inherent stereoselectivity of the Stille-coupling, only the Z-isomers were obtained. Further elaboration to FR900098 analogues 3a-e involved a BCl 3 -assisted removal of the benzyl protecting group from 8a-e. Subsequent cleavage of the phosphonate ester groups with TMSBr followed by purification by reversed phase HPLC yielded the Zconfigured analogues 3a-e in low to moderate yields. 17 A Suzuki-based strategy was chosen for the synthesis of the E-,-unsaturated analogues 4a,f-g (Scheme 3). First Z--bromo-1-propenyl phosphonate (11) was synthesized from diethyl phosphite (10) in two steps.
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The required Z-configuration was assigned based on the 3 J PH coupling constant (14.2 Hz) in the 1 H NMR spectrum, which is in accordance with the coupling constant typically found for a vinylic proton located cis to a phosphonate. 19 Radical allylic bromination afforded compound 12 in moderate yield. Prior conversion of the allylic bromide 12 into iodide 13 via Finkelstein reaction was required due to the low reactivity of compound 12 in the substitution reaction to yield key intermediate 6. Conversely, when this substitution reaction was applied to iodide 13, protected allylic hydroxylamine 6 was obtained in an adequate yield. Optimization of the Suzuki-coupling with a series of arylboronic acids (Scheme 4) proved to be troublesome, as poor to moderate yields were obtained for 14a,f-g. Furthermore, every analogue required different, specific conditions for the reaction to occur, in contrast to the generally applicable Stille-conditions described above. To complete the synthesis of analogues 4a,f-g, the Bocprotecting group of 14a,f-g was first removed, followed by in situ acetylation of the free amine to yield the Nbenzyloxyacetamides 15a,f-g. Subsequent removal of the benzyl protecting group with BCl 3 and cleavage of the phosphonate esters yielded the final E-configured ,-unsaturated, -aryl substituted analogues 4a,f-g, which were purified via Whatman CF-11 cellulose chromatography, resulting in much improved yields as compared to RP-chromatographic purification used for 3a-e. 19, 20 Furthermore, application of the same deprotection sequence directly on the vinylic bromide 6 also allowed for the synthesis of the Z-,-unsaturated -bromo-substituted analogue 19. Because of the difficulties associated with the handling of P. falciparum DXR, we investigated the ability of the synthesized FR900098 analogues 3a-e, 4a,f-g and 19 to inhibit the highly homologous E. coli isozyme. The conversion of DOXP to MEP by the enzyme was determined in an assay based on the NADPH dependency of the reaction and the results are summarized in Table 1 Compared to fosmidomycin and FR900098, the Zconfigured unsaturated analogues 3a-e were found to be much weaker inhibitors of E. coli DXR, which was anticipated considering the previously found preferred trans-orientation of the phosphonate and retrohydroxamate functionalities in cyclopropyl and cyclopentyl fosmidomycin analogues. 11, 15 Unexpectedly, in contrast with the active transsubstituted cyclopropyl derivative 2, also the Econfigured -aryl substituted FR900098 analogues 4a,f-g displayed poor inhibitory activity towards E. coli DXR. Apparently, the combination of an -aryl substituent and an ,-unsaturated bond constrains the rotational freedom in a way that is unfavorable for binding to active site of DXR. It should be noted that the relative conformation of two trans-substituents on a cyclopropane ring diverges from that of the transsubstituents in the E-configured analogues 4a,f-g. Remarkably, the -bromo derivative 19, capable of undergoing electronical interactions with the target enzyme, performs much better than analogues 3a-e and 4a,f-g.
In conclusion, two different divergent procedures for the preparation of both Z-and E-unsaturated α-aryl- 
